Tianjin Chase Sun Pharmaceutical Stock Forum

The market seems to be more cautious about the stock due to the lack of EPS growth. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering.

Despite the low ROE, Tianjin Chase Sun PharmaceuticalLtd's respectable earnings growth can be attributed to its efficient reinvestment of profits. The company's future growth rate is expected to maintain its current pace according to industry analyst forecasts.

Despite boosted earnings, Tianjin Chase Sun Pharmaceutical's low P/E ratio indicates investors' doubt over its ability to outperform the market. The low P/E ratio could hinder the share price if medium-term conditions don't improve.